Table IIA.
Trials of low molecular weight heparin versus placebo in patients with acute myocardial infarction
| Trial | Treatment | N | Setting | Duration | Death | Re-MI | Major Bleeds | Hemorrhagic Stroke |
|---|---|---|---|---|---|---|---|---|
| FRAMI 19979 | Dalteparin | 338 | Started 8 hrs after TT | Hospital period | 23 | 6 | 11 | 3 |
| Placebo | 338 | 23 | 8 | 1 | 0 | |||
| Glick 199610 | Clexane | 43 | Started 5 days after TT | 25 days | 0 | 2 | 0 | 0 |
| Placebo | 60 | 1 | 13 | 0 | 0 | |||
| BIOMACS II 199911 | Dalteparin | 54 | Adjunct to SK | 1 day | 4 | 8 | 2 | 0 |
| Placebo | 47 | 6 | 2 | 0 | 0 | |||
| AMI-SK12 | Enoxaparin | 253 | Adjunct to SK | 3–8 days | 17 | 6 | 12 | 0 |
| Placebo | 243 | 3–8 days | 17 | 18 | 6 | 1 | ||
| Total | LMWH vs. | 688 | – | – | 44 (6.4%) | 22 (3.2%) | 25 (3.6%) | 3 (0.44%) |
| Placebo | 688 | – | – | 47 (6.8%) | 41 (6.0%) | 7 (1.0%) | 1 (0.15%) | |
| OR (95% CI)* | – | – | – | 0.75(0.36–1.55) | 0.54(0.33–0.91) | 3.00(1.50–6.00) | 2.01(0.40–9.99) |
Re-MI, Reinfarction; TT, thrombolytic therapy; SK, streptokinase.
∗
The odds ratio (OR) and 95% confidence intervals (CI) are calculated using the Yusuf-Peto modification of the Mantel-Haenszel method.35